Financial Review: Viridian Therapeutics (NASDAQ:VRDN) and Immunome (NASDAQ:IMNM)

Viridian Therapeutics (NASDAQ:VRDN) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Viridian Therapeutics and Immunome”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85 million	26.23	-$342.60 million	($3.32)	-5.43
Immunome	$6.94 million	364.23	-$212.39 million	($2.38)	-9.38

Immunome has lower revenue, but higher earnings than Viridian Therapeutics. Immunome is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Viridian Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Immunome has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Institutional and Insider Ownership

44.6% of Immunome shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Viridian Therapeutics and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Immunome	N/A	-51.15%	-47.32%

Analyst Ratings

This is a breakdown of current ratings for Viridian Therapeutics and Immunome, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1	0	13	0	2.86
Immunome	1	0	13	0	2.86

Viridian Therapeutics currently has a consensus price target of $38.79, suggesting a potential upside of 115.12%. Immunome has a consensus price target of $33.17, suggesting a potential upside of 48.60%. Given Viridian Therapeutics’ higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Immunome.

Summary

Immunome beats Viridian Therapeutics on 9 of the 12 factors compared between the two stocks.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.